[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.7314/APJCP.2012.13.4.1097

Pristimerin Inhibits Breast Cancer Cell Migration by Up-regulating Regulator of G Protein Signaling 4 Expression

Mu, Xian-Min (Jiangsu Center of Drug Screening, China Pharmaceutical University)
Shi, Wei (Department of New Drug Screening, Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd,)
Sun, Li-Xin (Jiangsu Center of Drug Screening, China Pharmaceutical University)
Li, Han (Jiangsu Center of Drug Screening, China Pharmaceutical University)
Wang, Yu-Rong (Jiangsu Center of Drug Screening, China Pharmaceutical University)
Jiang, Zhen-Zhou (Jiangsu Center of Drug Screening, China Pharmaceutical University)
Zhang, Lu-Yong (Jiangsu Center of Drug Screening, China Pharmaceutical University)

Publication Information

Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1097-1104 More about this Journal

Abstract

Background/Aim: Pristimerin isolated from Celastrus and Maytenus spp can inhibit proteasome activity. However, whether pristimerin can modulate cancer metastasis is unknown. Methods: The impacts of pristimerin on the purified and intracellular chymotrypsin proteasomal activity, the levels of regulator of G protein signaling 4 (RGS 4) expression and breast cancer cell lamellipodia formation, and the migration and invasion were determined by enzymatic, Western blot, immunofluorescent, and transwell assays, respectively. Results: We found that pristimerin inhibited human chymotrypsin proteasomal activity in MDA-MB-231 cells in a dose-dependent manner. Pristimerin also inhibited breast cancer cell lamellipodia formation, migration, and invasion in vitro by up-regulating RGS4 expression. Thus, knockdown of RGS4 attenuated pristimerin-mediated inhibition of breast cancer cell migration and invasion. Furthermore, pristimerin inhibited growth and invasion of implanted breast tumors in mice. Conclusion: Pristmerin inhibits proteasomal activity and increases the levels of RGS4, inhibiting the migration and invasion of breast cancer cells.

Keywords

Pristimerin; anti-cancer; proteasome inhibition; RGS4; breast cancer;

Citations & Related Records

Reference

1	Adams J (2003). The proteasome: structure, function, and role in the cell. Cancer Treat Rev, 29 Suppl 1, 3-9.
2	Albig AR SW (2005). Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis. Mol Biol Cell, 16, 609-25.
3	Bodenstein J, Sunahara RK, Neubig RR (2007). N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. Mol Pharmacol, 71, 1040-50. DOI
4	Boire A, Covic L, Agarwal A, et al (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell, 120, 303-13. DOI ScienceOn
5	Byun JY, Kim MJ, Eum DY, et al (2009). Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol, 76, 734-44. DOI
6	Chambers AF, Groom AC, MacDonald IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer, 2, 563-72. DOI
7	Chen L, Madura K (2005). Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res, 65, 5599-606. DOI
8	Costa PM, Ferreira PM, Bolzani Vda S, et al (2008). Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro, 22, 854-63. DOI
9	Dahlmann B (2007). Role of proteasomes in disease. BMC Biochem, 8 Suppl 1, S3. DOI
10	Dorsam RT, Gutkind JS (2007). G-protein-coupled receptors and cancer. Nat Rev Cancer, 7, 79-94. DOI ScienceOn
11	Glickman MH, Ciechanover A (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev, 82, 373-428.
12	Lappano R, Maggiolini M (2011). G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov, 10, 47-60. DOI ScienceOn
13	Hobson JP, Rosenfeldt HM, Barak LS, et al (2001). Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science, 291, 1800-3. DOI
14	Huang C, Hepler JR, Gilman AG, et al. (1997). Attenuation of Gi- and Gq-mediated signaling by expression of RGS4 or GAIP in mammalian cells. Proc Natl Acad Sci U S A, 94, 6159-63. DOI
15	Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI
16	Lee MJ, Tasaki T, Moroi K, et al (2005). RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. Proc Natl Acad Sci U S A, 102, 15030-5. DOI
17	Neves SR, Ram PT, Iyengar R (2002). G protein pathways. Science, 296, 1636-9. DOI ScienceOn
18	Ross EM, Wilkie TM (2000). GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem, 69, 795-827. DOI ScienceOn
19	Schlunck G, Damke H, Kiosses WB, et al (2004). Modulation of Rac localization and function by dynamin. Mol Biol Cell, 15, 256-67.
20	Schwartz AL, Ciechanover A (2009). Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol, 49, 73-96. DOI
21	Tiedemann RE, Schmidt J, Keats JJ, et al (2009). Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood, 113, 4027-37. DOI
22	Wu CC, Chan ML, Chen WY, et al (2005). Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther, 4, 1277-85. DOI
23	Valentiner U, Haane C, Nehmann N, et al (2009). Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Anticancer Res, 29, 1219-25.
24	Van Haastert PJ, Devreotes PN (2004). Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol, 5, 626-34. DOI
25	Varshavsky IVDaA (2000). RGS4 is arginylated and degraded by the N-end rule pathway in vitro. J Biol Chem, 275, 22931-41. DOI
26	Xie GX PP (2007 ). How regulators of G protein signaling achieve selective regulation. J Mol Biol, 366, 349-65. DOI
27	Xie Y, Wolff DW, Wei T, et al (2009). Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res, 69, 5743-51. DOI
28	Yamada H, Abe T, Li SA, et al (2009). Dynasore, a dynamin inhibitor, suppresses lamellipodia formation and cancer cell invasion by destabilizing actin filaments. Biochem Biophys Res Commun, 390, 1142-8. DOI
29	Yang H, Landis-Piwowar KR, Lu D, et al (2008). Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem, 103, 234-44. DOI
30	Yau C, Esserman L, Moore DH, et al (2010). A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res, 12, R85. DOI

Reference

5	(2014) International Journal of Oncology Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2 / 44 (5) , 1707
4	(2014) International Journal of Oncology Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin / 45 (4) , 1735
8	Ebtihal H Mustafa. (2015) Asian Pacific Journal of Cancer Prevention 2-deoxy-D-Glucose Synergizes with Doxorubicin or L-Buthionine Sulfoximine to Reduce Adhesion and Migration of Breast Cancer Cells / 16 (8) , 3213
6	Zumin Xu. (2015) Oncology Reports Overexpression of the regulator of G-protein signaling 5 reduces the survival rate and enhances the radiation response of human lung cancer cells / 33 (6) , 2899
1	Seon-Ok Lee. (2016) BMC Cancer Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells / 16 (1)
5	(2016) Oncology Letters Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling / 11 (5) , 3111
1663-9812	(2018) Frontiers in Pharmacology Fatty Acids Rich Extract From Clerodendrum volubile Suppresses Cell Migration; Abates Oxidative Stress; and Regulates Cell Cycle Progression in Glioblastoma Multiforme (U87 MG) Cells / 9 (1663-9812)